nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—MAP2K2—endometrium—vaginal cancer	0.00138	0.00194	CbGeAlD
Bosutinib—MAP3K7—urethra—vaginal cancer	0.00138	0.00194	CbGeAlD
Bosutinib—BTK—vagina—vaginal cancer	0.00137	0.00193	CbGeAlD
Bosutinib—EGFR—uterus—vaginal cancer	0.00137	0.00193	CbGeAlD
Bosutinib—SIK1—mammalian vulva—vaginal cancer	0.00136	0.00192	CbGeAlD
Bosutinib—IRAK4—mammalian vulva—vaginal cancer	0.00136	0.00192	CbGeAlD
Bosutinib—TBK1—urethra—vaginal cancer	0.00136	0.00192	CbGeAlD
Bosutinib—PTK2—urethra—vaginal cancer	0.00136	0.00192	CbGeAlD
Bosutinib—TNK2—female gonad—vaginal cancer	0.00136	0.00192	CbGeAlD
Bosutinib—EPHB4—epithelium—vaginal cancer	0.00136	0.00191	CbGeAlD
Bosutinib—SLK—uterine cervix—vaginal cancer	0.00136	0.00191	CbGeAlD
Bosutinib—MAP3K7—endometrium—vaginal cancer	0.00136	0.00191	CbGeAlD
Bosutinib—EPHA4—mammalian vulva—vaginal cancer	0.00135	0.0019	CbGeAlD
Bosutinib—EPHB4—uterine cervix—vaginal cancer	0.00135	0.0019	CbGeAlD
Bosutinib—MAP4K4—female reproductive system—vaginal cancer	0.00134	0.00189	CbGeAlD
Bosutinib—MAP4K2—female gonad—vaginal cancer	0.00134	0.00189	CbGeAlD
Bosutinib—TBK1—endometrium—vaginal cancer	0.00134	0.00189	CbGeAlD
Bosutinib—EPHA2—epithelium—vaginal cancer	0.00134	0.00188	CbGeAlD
Bosutinib—MAP4K2—vagina—vaginal cancer	0.00134	0.00188	CbGeAlD
Bosutinib—MAP2K2—mammalian vulva—vaginal cancer	0.00133	0.00188	CbGeAlD
Bosutinib—ULK3—mammalian vulva—vaginal cancer	0.00133	0.00188	CbGeAlD
Bosutinib—BCR—female reproductive system—vaginal cancer	0.00133	0.00188	CbGeAlD
Bosutinib—STK3—female gonad—vaginal cancer	0.00133	0.00186	CbGeAlD
Bosutinib—MAP3K12—female reproductive system—vaginal cancer	0.00132	0.00186	CbGeAlD
Bosutinib—EPHA2—uterine cervix—vaginal cancer	0.00132	0.00186	CbGeAlD
Bosutinib—FYN—uterine cervix—vaginal cancer	0.00132	0.00186	CbGeAlD
Bosutinib—CSNK1E—uterus—vaginal cancer	0.00132	0.00186	CbGeAlD
Bosutinib—ERBB4—vagina—vaginal cancer	0.00132	0.00185	CbGeAlD
Bosutinib—STK3—vagina—vaginal cancer	0.00132	0.00185	CbGeAlD
Bosutinib—MAP3K7—mammalian vulva—vaginal cancer	0.00131	0.00185	CbGeAlD
Bosutinib—RPS6KB1—urethra—vaginal cancer	0.00131	0.00184	CbGeAlD
Bosutinib—ROCK1—female gonad—vaginal cancer	0.00131	0.00184	CbGeAlD
Bosutinib—LCK—urethra—vaginal cancer	0.0013	0.00183	CbGeAlD
Bosutinib—FGR—urethra—vaginal cancer	0.0013	0.00183	CbGeAlD
Bosutinib—SIK1—uterus—vaginal cancer	0.0013	0.00183	CbGeAlD
Bosutinib—MAP2K1—female reproductive system—vaginal cancer	0.0013	0.00183	CbGeAlD
Bosutinib—STK35—female reproductive system—vaginal cancer	0.0013	0.00183	CbGeAlD
Bosutinib—AXL—urethra—vaginal cancer	0.0013	0.00182	CbGeAlD
Bosutinib—TBK1—mammalian vulva—vaginal cancer	0.0013	0.00182	CbGeAlD
Bosutinib—MAP3K3—uterine cervix—vaginal cancer	0.00129	0.00182	CbGeAlD
Bosutinib—MAP4K5—uterine cervix—vaginal cancer	0.00129	0.00182	CbGeAlD
Bosutinib—RPS6KB1—endometrium—vaginal cancer	0.00129	0.00181	CbGeAlD
Bosutinib—CSK—female reproductive system—vaginal cancer	0.00129	0.00181	CbGeAlD
Bosutinib—EPHA4—uterus—vaginal cancer	0.00129	0.00181	CbGeAlD
Bosutinib—FGR—endometrium—vaginal cancer	0.00128	0.0018	CbGeAlD
Bosutinib—CSNK1A1—female reproductive system—vaginal cancer	0.00128	0.0018	CbGeAlD
Bosutinib—AXL—endometrium—vaginal cancer	0.00128	0.0018	CbGeAlD
Bosutinib—ERBB3—uterus—vaginal cancer	0.00127	0.00179	CbGeAlD
Bosutinib—CLK1—female reproductive system—vaginal cancer	0.00127	0.00179	CbGeAlD
Bosutinib—IRAK1—mammalian vulva—vaginal cancer	0.00127	0.00179	CbGeAlD
Bosutinib—MAP2K2—uterus—vaginal cancer	0.00127	0.00179	CbGeAlD
Bosutinib—ULK3—uterus—vaginal cancer	0.00127	0.00179	CbGeAlD
Bosutinib—BMPR2—female gonad—vaginal cancer	0.00127	0.00179	CbGeAlD
Bosutinib—BMPR2—vagina—vaginal cancer	0.00126	0.00178	CbGeAlD
Bosutinib—MAP3K2—uterus—vaginal cancer	0.00126	0.00177	CbGeAlD
Bosutinib—EPHB3—female gonad—vaginal cancer	0.00126	0.00177	CbGeAlD
Bosutinib—STK36—female gonad—vaginal cancer	0.00126	0.00177	CbGeAlD
Bosutinib—EPHB3—vagina—vaginal cancer	0.00125	0.00176	CbGeAlD
Bosutinib—STK36—vagina—vaginal cancer	0.00125	0.00176	CbGeAlD
Bosutinib—MAP3K7—uterus—vaginal cancer	0.00125	0.00176	CbGeAlD
Bosutinib—CAMK2G—female reproductive system—vaginal cancer	0.00125	0.00176	CbGeAlD
Bosutinib—BMP2K—female reproductive system—vaginal cancer	0.00125	0.00176	CbGeAlD
Bosutinib—SLK—urethra—vaginal cancer	0.00125	0.00176	CbGeAlD
Bosutinib—RPS6KB1—mammalian vulva—vaginal cancer	0.00125	0.00175	CbGeAlD
Bosutinib—MERTK—female gonad—vaginal cancer	0.00125	0.00175	CbGeAlD
Bosutinib—LCK—mammalian vulva—vaginal cancer	0.00124	0.00174	CbGeAlD
Bosutinib—FGR—mammalian vulva—vaginal cancer	0.00124	0.00174	CbGeAlD
Bosutinib—EPHB4—urethra—vaginal cancer	0.00124	0.00174	CbGeAlD
Bosutinib—MERTK—vagina—vaginal cancer	0.00124	0.00174	CbGeAlD
Bosutinib—LRRK2—female reproductive system—vaginal cancer	0.00124	0.00174	CbGeAlD
Bosutinib—PTK2—uterus—vaginal cancer	0.00124	0.00174	CbGeAlD
Bosutinib—AXL—mammalian vulva—vaginal cancer	0.00124	0.00174	CbGeAlD
Bosutinib—SLK—endometrium—vaginal cancer	0.00123	0.00173	CbGeAlD
Bosutinib—MAP4K4—female gonad—vaginal cancer	0.00122	0.00172	CbGeAlD
Bosutinib—EPHB4—endometrium—vaginal cancer	0.00122	0.00172	CbGeAlD
Bosutinib—EPHA2—urethra—vaginal cancer	0.00122	0.00171	CbGeAlD
Bosutinib—MAP4K4—vagina—vaginal cancer	0.00122	0.00171	CbGeAlD
Bosutinib—FYN—urethra—vaginal cancer	0.00121	0.00171	CbGeAlD
Bosutinib—BCR—female gonad—vaginal cancer	0.00121	0.00171	CbGeAlD
Bosutinib—NUAK2—female gonad—vaginal cancer	0.00121	0.00171	CbGeAlD
Bosutinib—NUAK2—vagina—vaginal cancer	0.00121	0.0017	CbGeAlD
Bosutinib—BCR—vagina—vaginal cancer	0.00121	0.0017	CbGeAlD
Bosutinib—PTK2B—female reproductive system—vaginal cancer	0.00121	0.0017	CbGeAlD
Bosutinib—MAP3K12—female gonad—vaginal cancer	0.00121	0.0017	CbGeAlD
Bosutinib—MAP3K12—vagina—vaginal cancer	0.0012	0.00168	CbGeAlD
Bosutinib—EPHA2—endometrium—vaginal cancer	0.0012	0.00168	CbGeAlD
Bosutinib—FYN—endometrium—vaginal cancer	0.0012	0.00168	CbGeAlD
Bosutinib—YES1—uterine cervix—vaginal cancer	0.00119	0.00168	CbGeAlD
Bosutinib—SLK—mammalian vulva—vaginal cancer	0.00119	0.00167	CbGeAlD
Bosutinib—CSNK1E—female reproductive system—vaginal cancer	0.00119	0.00167	CbGeAlD
Bosutinib—MAP4K5—urethra—vaginal cancer	0.00119	0.00167	CbGeAlD
Bosutinib—MAP3K3—urethra—vaginal cancer	0.00119	0.00167	CbGeAlD
Bosutinib—STK10—uterine cervix—vaginal cancer	0.00118	0.00166	CbGeAlD
Bosutinib—LCK—uterus—vaginal cancer	0.00118	0.00166	CbGeAlD
Bosutinib—MAP2K1—female gonad—vaginal cancer	0.00118	0.00166	CbGeAlD
Bosutinib—STK35—female gonad—vaginal cancer	0.00118	0.00166	CbGeAlD
Bosutinib—EPHB4—mammalian vulva—vaginal cancer	0.00118	0.00166	CbGeAlD
Bosutinib—TAOK3—uterine cervix—vaginal cancer	0.00118	0.00166	CbGeAlD
Bosutinib—AXL—uterus—vaginal cancer	0.00118	0.00165	CbGeAlD
Bosutinib—STK35—vagina—vaginal cancer	0.00117	0.00165	CbGeAlD
Bosutinib—CSK—female gonad—vaginal cancer	0.00117	0.00165	CbGeAlD
Bosutinib—SIK1—female reproductive system—vaginal cancer	0.00117	0.00164	CbGeAlD
Bosutinib—MAP4K5—endometrium—vaginal cancer	0.00117	0.00164	CbGeAlD
Bosutinib—MAP3K3—endometrium—vaginal cancer	0.00117	0.00164	CbGeAlD
Bosutinib—CSK—vagina—vaginal cancer	0.00117	0.00164	CbGeAlD
Bosutinib—CSNK1A1—female gonad—vaginal cancer	0.00117	0.00164	CbGeAlD
Bosutinib—CSNK1A1—vagina—vaginal cancer	0.00116	0.00163	CbGeAlD
Bosutinib—EPHA2—mammalian vulva—vaginal cancer	0.00116	0.00163	CbGeAlD
Bosutinib—HCK—female gonad—vaginal cancer	0.00116	0.00163	CbGeAlD
Bosutinib—CLK1—female gonad—vaginal cancer	0.00116	0.00163	CbGeAlD
Bosutinib—SRC—epithelium—vaginal cancer	0.00116	0.00163	CbGeAlD
Bosutinib—EPHA4—female reproductive system—vaginal cancer	0.00116	0.00163	CbGeAlD
Bosutinib—FYN—mammalian vulva—vaginal cancer	0.00116	0.00163	CbGeAlD
Bosutinib—HCK—vagina—vaginal cancer	0.00115	0.00162	CbGeAlD
Bosutinib—CLK1—vagina—vaginal cancer	0.00115	0.00162	CbGeAlD
Bosutinib—ABL2—female gonad—vaginal cancer	0.00115	0.00162	CbGeAlD
Bosutinib—SRC—uterine cervix—vaginal cancer	0.00115	0.00161	CbGeAlD
Bosutinib—ERBB3—female reproductive system—vaginal cancer	0.00115	0.00161	CbGeAlD
Bosutinib—ABL2—vagina—vaginal cancer	0.00114	0.00161	CbGeAlD
Bosutinib—ULK3—female reproductive system—vaginal cancer	0.00114	0.00161	CbGeAlD
Bosutinib—MAP2K2—female reproductive system—vaginal cancer	0.00114	0.00161	CbGeAlD
Bosutinib—CAMK2G—female gonad—vaginal cancer	0.00114	0.0016	CbGeAlD
Bosutinib—BMP2K—female gonad—vaginal cancer	0.00114	0.0016	CbGeAlD
Bosutinib—MAP3K2—female reproductive system—vaginal cancer	0.00113	0.0016	CbGeAlD
Bosutinib—SLK—uterus—vaginal cancer	0.00113	0.00159	CbGeAlD
Bosutinib—MAP4K5—mammalian vulva—vaginal cancer	0.00113	0.00159	CbGeAlD
Bosutinib—MAP3K3—mammalian vulva—vaginal cancer	0.00113	0.00159	CbGeAlD
Bosutinib—CAMK2G—vagina—vaginal cancer	0.00113	0.00159	CbGeAlD
Bosutinib—BMP2K—vagina—vaginal cancer	0.00113	0.00159	CbGeAlD
Bosutinib—LRRK2—female gonad—vaginal cancer	0.00113	0.00158	CbGeAlD
Bosutinib—EPHB4—uterus—vaginal cancer	0.00112	0.00158	CbGeAlD
Bosutinib—EGFR—female gonad—vaginal cancer	0.00112	0.00158	CbGeAlD
Bosutinib—LRRK2—vagina—vaginal cancer	0.00112	0.00157	CbGeAlD
Bosutinib—PTK2—female reproductive system—vaginal cancer	0.00111	0.00156	CbGeAlD
Bosutinib—TBK1—female reproductive system—vaginal cancer	0.00111	0.00156	CbGeAlD
Bosutinib—FYN—uterus—vaginal cancer	0.0011	0.00155	CbGeAlD
Bosutinib—PTK2B—female gonad—vaginal cancer	0.0011	0.00154	CbGeAlD
Bosutinib—YES1—urethra—vaginal cancer	0.0011	0.00154	CbGeAlD
Bosutinib—PTK2B—vagina—vaginal cancer	0.00109	0.00153	CbGeAlD
Bosutinib—IRAK1—female reproductive system—vaginal cancer	0.00109	0.00153	CbGeAlD
Bosutinib—TAOK3—urethra—vaginal cancer	0.00108	0.00152	CbGeAlD
Bosutinib—CSNK1E—female gonad—vaginal cancer	0.00108	0.00152	CbGeAlD
Bosutinib—YES1—endometrium—vaginal cancer	0.00108	0.00152	CbGeAlD
Bosutinib—MAP4K5—uterus—vaginal cancer	0.00108	0.00151	CbGeAlD
Bosutinib—CSNK1E—vagina—vaginal cancer	0.00107	0.00151	CbGeAlD
Bosutinib—RPS6KB1—female reproductive system—vaginal cancer	0.00107	0.0015	CbGeAlD
Bosutinib—TAOK3—endometrium—vaginal cancer	0.00107	0.0015	CbGeAlD
Bosutinib—TBK1—Immune System—EIF4A3—vaginal cancer	0.00106	0.00368	CbGpPWpGaD
Bosutinib—SIK1—female gonad—vaginal cancer	0.00106	0.0015	CbGeAlD
Bosutinib—IRAK4—female gonad—vaginal cancer	0.00106	0.0015	CbGeAlD
Bosutinib—FGR—female reproductive system—vaginal cancer	0.00106	0.00149	CbGeAlD
Bosutinib—AXL—female reproductive system—vaginal cancer	0.00106	0.00149	CbGeAlD
Bosutinib—IRAK4—vagina—vaginal cancer	0.00106	0.00149	CbGeAlD
Bosutinib—MAP2K5—uterine cervix—vaginal cancer	0.00106	0.00148	CbGeAlD
Bosutinib—EPHA4—female gonad—vaginal cancer	0.00105	0.00148	CbGeAlD
Bosutinib—FYN—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00105	0.00364	CbGpPWpGaD
Bosutinib—MAP2K1—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00105	0.00362	CbGpPWpGaD
Bosutinib—EPHA4—vagina—vaginal cancer	0.00105	0.00147	CbGeAlD
Bosutinib—CAMK2G—Immune System—EIF4A3—vaginal cancer	0.00104	0.00362	CbGpPWpGaD
Bosutinib—YES1—mammalian vulva—vaginal cancer	0.00104	0.00147	CbGeAlD
Bosutinib—ERBB3—female gonad—vaginal cancer	0.00104	0.00147	CbGeAlD
Bosutinib—HCK—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00104	0.00361	CbGpPWpGaD
Bosutinib—ULK3—female gonad—vaginal cancer	0.00104	0.00146	CbGeAlD
Bosutinib—MAP2K2—female gonad—vaginal cancer	0.00104	0.00146	CbGeAlD
Bosutinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00104	0.0036	CbGpPWpGaD
Bosutinib—MAP3K3—Signaling by Interleukins—IL2—vaginal cancer	0.00103	0.00358	CbGpPWpGaD
Bosutinib—STK10—mammalian vulva—vaginal cancer	0.00103	0.00145	CbGeAlD
Bosutinib—ULK3—vagina—vaginal cancer	0.00103	0.00145	CbGeAlD
Bosutinib—MAP3K2—female gonad—vaginal cancer	0.00103	0.00145	CbGeAlD
Bosutinib—TAOK3—mammalian vulva—vaginal cancer	0.00103	0.00145	CbGeAlD
Bosutinib—CSF1R—uterine cervix—vaginal cancer	0.00103	0.00145	CbGeAlD
Bosutinib—LYN—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00103	0.00357	CbGpPWpGaD
Bosutinib—MAP3K7—female gonad—vaginal cancer	0.00102	0.00144	CbGeAlD
Bosutinib—MAP2K2—Interleukin-2 signaling—IL2—vaginal cancer	0.00102	0.00354	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—EIF4A3—vaginal cancer	0.00102	0.00353	CbGpPWpGaD
Bosutinib—MAP3K7—vagina—vaginal cancer	0.00102	0.00143	CbGeAlD
Bosutinib—FYN—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00101	0.00351	CbGpPWpGaD
Bosutinib—EPHB4—female reproductive system—vaginal cancer	0.00101	0.00142	CbGeAlD
Bosutinib—PTK2—female gonad—vaginal cancer	0.00101	0.00142	CbGeAlD
Bosutinib—TBK1—female gonad—vaginal cancer	0.00101	0.00142	CbGeAlD
Bosutinib—TBK1—vagina—vaginal cancer	0.001	0.00141	CbGeAlD
Bosutinib—PTK2—vagina—vaginal cancer	0.001	0.00141	CbGeAlD
Bosutinib—ABL1—Factors involved in megakaryocyte development and platelet production—IFNA1—vaginal cancer	0.001	0.00348	CbGpPWpGaD
Bosutinib—YES1—uterus—vaginal cancer	0.000994	0.0014	CbGeAlD
Bosutinib—BTK—Immune System—EIF4A3—vaginal cancer	0.000992	0.00344	CbGpPWpGaD
Bosutinib—EPHA2—female reproductive system—vaginal cancer	0.000992	0.00139	CbGeAlD
Bosutinib—IRAK1—female gonad—vaginal cancer	0.000991	0.00139	CbGeAlD
Bosutinib—FYN—female reproductive system—vaginal cancer	0.00099	0.00139	CbGeAlD
Bosutinib—CDK2—Spinal Cord Injury—IL2—vaginal cancer	0.000987	0.00342	CbGpPWpGaD
Bosutinib—STK10—uterus—vaginal cancer	0.000985	0.00139	CbGeAlD
Bosutinib—TAOK3—uterus—vaginal cancer	0.000981	0.00138	CbGeAlD
Bosutinib—RPS6KB1—female gonad—vaginal cancer	0.000973	0.00137	CbGeAlD
Bosutinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.000971	0.00336	CbGpPWpGaD
Bosutinib—MAP2K5—urethra—vaginal cancer	0.00097	0.00136	CbGeAlD
Bosutinib—LCK—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.000969	0.00336	CbGpPWpGaD
Bosutinib—MAP3K3—female reproductive system—vaginal cancer	0.000968	0.00136	CbGeAlD
Bosutinib—MAP4K5—female reproductive system—vaginal cancer	0.000968	0.00136	CbGeAlD
Bosutinib—PTK2B—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000968	0.00335	CbGpPWpGaD
Bosutinib—RPS6KB1—vagina—vaginal cancer	0.000967	0.00136	CbGeAlD
Bosutinib—FGR—female gonad—vaginal cancer	0.000967	0.00136	CbGeAlD
Bosutinib—LCK—female gonad—vaginal cancer	0.000967	0.00136	CbGeAlD
Bosutinib—AXL—female gonad—vaginal cancer	0.000963	0.00135	CbGeAlD
Bosutinib—IRAK4—Signaling by Interleukins—IL2—vaginal cancer	0.000962	0.00333	CbGpPWpGaD
Bosutinib—LCK—vagina—vaginal cancer	0.000961	0.00135	CbGeAlD
Bosutinib—FGR—vagina—vaginal cancer	0.000961	0.00135	CbGeAlD
Bosutinib—AXL—vagina—vaginal cancer	0.000957	0.00135	CbGeAlD
Bosutinib—MAP2K1—Interleukin-2 signaling—IL2—vaginal cancer	0.000956	0.00331	CbGpPWpGaD
Bosutinib—MAP2K5—endometrium—vaginal cancer	0.000955	0.00134	CbGeAlD
Bosutinib—IRAK4—Immune System—EIF4A3—vaginal cancer	0.000948	0.00328	CbGpPWpGaD
Bosutinib—CSF1R—urethra—vaginal cancer	0.000947	0.00133	CbGeAlD
Bosutinib—LYN—GPVI-mediated activation cascade—IL2—vaginal cancer	0.000945	0.00327	CbGpPWpGaD
Bosutinib—CSF1R—endometrium—vaginal cancer	0.000932	0.00131	CbGeAlD
Bosutinib—FYN—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00093	0.00322	CbGpPWpGaD
Bosutinib—SLK—female gonad—vaginal cancer	0.000927	0.0013	CbGeAlD
Bosutinib—HCK—Signaling by Interleukins—IL2—vaginal cancer	0.000924	0.0032	CbGpPWpGaD
Bosutinib—MAP2K5—mammalian vulva—vaginal cancer	0.000924	0.0013	CbGeAlD
Bosutinib—PDGFRB—epithelium—vaginal cancer	0.000922	0.0013	CbGeAlD
Bosutinib—SLK—vagina—vaginal cancer	0.000921	0.0013	CbGeAlD
Bosutinib—EPHB4—female gonad—vaginal cancer	0.00092	0.00129	CbGeAlD
Bosutinib—IKBKE—Innate Immune System—IFNA1—vaginal cancer	0.000919	0.00318	CbGpPWpGaD
Bosutinib—MAP2K2—IL2-mediated signaling events—IL2—vaginal cancer	0.000915	0.00317	CbGpPWpGaD
Bosutinib—EPHB4—vagina—vaginal cancer	0.000915	0.00129	CbGeAlD
Bosutinib—PDGFRB—uterine cervix—vaginal cancer	0.000914	0.00128	CbGeAlD
Bosutinib—HCK—Immune System—EIF4A3—vaginal cancer	0.000911	0.00315	CbGpPWpGaD
Bosutinib—EPHA2—female gonad—vaginal cancer	0.000903	0.00127	CbGeAlD
Bosutinib—CSF1R—mammalian vulva—vaginal cancer	0.000901	0.00127	CbGeAlD
Bosutinib—FYN—female gonad—vaginal cancer	0.000901	0.00127	CbGeAlD
Bosutinib—EPHA2—vagina—vaginal cancer	0.000897	0.00126	CbGeAlD
Bosutinib—FYN—vagina—vaginal cancer	0.000896	0.00126	CbGeAlD
Bosutinib—YES1—female reproductive system—vaginal cancer	0.000894	0.00126	CbGeAlD
Bosutinib—SYK—Hemostasis—IFNA1—vaginal cancer	0.000892	0.00309	CbGpPWpGaD
Bosutinib—STK10—female reproductive system—vaginal cancer	0.000886	0.00125	CbGeAlD
Bosutinib—TAOK3—female reproductive system—vaginal cancer	0.000882	0.00124	CbGeAlD
Bosutinib—MAP3K3—female gonad—vaginal cancer	0.000881	0.00124	CbGeAlD
Bosutinib—MAP4K5—female gonad—vaginal cancer	0.000881	0.00124	CbGeAlD
Bosutinib—LCK—IL-2 Signaling Pathway—IL2—vaginal cancer	0.000876	0.00303	CbGpPWpGaD
Bosutinib—PRKCQ—Hemostasis—IFNA1—vaginal cancer	0.000876	0.00303	CbGpPWpGaD
Bosutinib—MAP4K5—vagina—vaginal cancer	0.000875	0.00123	CbGeAlD
Bosutinib—MAP3K3—vagina—vaginal cancer	0.000875	0.00123	CbGeAlD
Bosutinib—MAP2K2—SHP2 signaling—IL2—vaginal cancer	0.000864	0.00299	CbGpPWpGaD
Bosutinib—FYN—IL2-mediated signaling events—IL2—vaginal cancer	0.00086	0.00298	CbGpPWpGaD
Bosutinib—SRC—female reproductive system—vaginal cancer	0.00086	0.00121	CbGeAlD
Bosutinib—CSF1R—uterus—vaginal cancer	0.000859	0.00121	CbGeAlD
Bosutinib—ERBB4—Immune System—EIF4A3—vaginal cancer	0.000858	0.00297	CbGpPWpGaD
Bosutinib—PTK2B—Signaling by Interleukins—IL2—vaginal cancer	0.000857	0.00297	CbGpPWpGaD
Bosutinib—MAP2K1—IL2-mediated signaling events—IL2—vaginal cancer	0.000856	0.00296	CbGpPWpGaD
Bosutinib—CSK—Hemostasis—IFNA1—vaginal cancer	0.000846	0.00293	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—EIF4A3—vaginal cancer	0.000845	0.00293	CbGpPWpGaD
Bosutinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.000845	0.00293	CbGpPWpGaD
Bosutinib—PDGFRB—SHP2 signaling—IL2—vaginal cancer	0.000843	0.00292	CbGpPWpGaD
Bosutinib—PDGFRB—urethra—vaginal cancer	0.00084	0.00118	CbGeAlD
Bosutinib—SRMS—Immune System—IFNA1—vaginal cancer	0.000831	0.00288	CbGpPWpGaD
Bosutinib—PDGFRB—endometrium—vaginal cancer	0.000826	0.00116	CbGeAlD
Bosutinib—BLK—Immune System—EIF4A3—vaginal cancer	0.000825	0.00286	CbGpPWpGaD
Bosutinib—FGR—Immune System—EIF4A3—vaginal cancer	0.000822	0.00285	CbGpPWpGaD
Bosutinib—ABL1—uterine cervix—vaginal cancer	0.000814	0.00115	CbGeAlD
Bosutinib—YES1—female gonad—vaginal cancer	0.000813	0.00114	CbGeAlD
Bosutinib—MAP2K1—SHP2 signaling—IL2—vaginal cancer	0.000808	0.0028	CbGpPWpGaD
Bosutinib—YES1—vagina—vaginal cancer	0.000808	0.00114	CbGeAlD
Bosutinib—STK10—female gonad—vaginal cancer	0.000806	0.00113	CbGeAlD
Bosutinib—MERTK—Hemostasis—IL2—vaginal cancer	0.000804	0.00278	CbGpPWpGaD
Bosutinib—SYK—Innate Immune System—IFNA1—vaginal cancer	0.000803	0.00278	CbGpPWpGaD
Bosutinib—TAOK3—female gonad—vaginal cancer	0.000803	0.00113	CbGeAlD
Bosutinib—STK10—vagina—vaginal cancer	0.000801	0.00113	CbGeAlD
Bosutinib—LCK—Interleukin-2 signaling—IL2—vaginal cancer	0.000801	0.00277	CbGpPWpGaD
Bosutinib—PDGFRB—mammalian vulva—vaginal cancer	0.000799	0.00112	CbGeAlD
Bosutinib—TAOK3—vagina—vaginal cancer	0.000798	0.00112	CbGeAlD
Bosutinib—MAP2K5—female reproductive system—vaginal cancer	0.000791	0.00111	CbGeAlD
Bosutinib—PRKCQ—Innate Immune System—IFNA1—vaginal cancer	0.000788	0.00273	CbGpPWpGaD
Bosutinib—SRC—female gonad—vaginal cancer	0.000782	0.0011	CbGeAlD
Bosutinib—MAP2K2—Downstream signaling in naïve CD8+ T cells—IL2—vaginal cancer	0.000779	0.0027	CbGpPWpGaD
Bosutinib—PTK2—Corticotropin-releasing hormone—IL2—vaginal cancer	0.000776	0.00269	CbGpPWpGaD
Bosutinib—LCK—GPVI-mediated activation cascade—IL2—vaginal cancer	0.000774	0.00268	CbGpPWpGaD
Bosutinib—CSF1R—female reproductive system—vaginal cancer	0.000772	0.00109	CbGeAlD
Bosutinib—PDGFRB—uterus—vaginal cancer	0.000762	0.00107	CbGeAlD
Bosutinib—YES1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00076	0.00263	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—EIF4A3—vaginal cancer	0.000756	0.00262	CbGpPWpGaD
Bosutinib—ABL1—urethra—vaginal cancer	0.000748	0.00105	CbGeAlD
Bosutinib—CDK2—Hemostasis—IFNA1—vaginal cancer	0.000745	0.00258	CbGpPWpGaD
Bosutinib—ABL1—endometrium—vaginal cancer	0.000737	0.00104	CbGeAlD
Bosutinib—MAP2K1—Downstream signaling in naïve CD8+ T cells—IL2—vaginal cancer	0.000729	0.00252	CbGpPWpGaD
Bosutinib—ABL1—Regulation of Telomerase—IL2—vaginal cancer	0.000723	0.00251	CbGpPWpGaD
Bosutinib—SRC—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.000721	0.0025	CbGpPWpGaD
Bosutinib—IRAK1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000721	0.0025	CbGpPWpGaD
Bosutinib—MAP2K5—female gonad—vaginal cancer	0.00072	0.00101	CbGeAlD
Bosutinib—LCK—IL2-mediated signaling events—IL2—vaginal cancer	0.000716	0.00248	CbGpPWpGaD
Bosutinib—SYK—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000716	0.00248	CbGpPWpGaD
Bosutinib—MAP2K5—vagina—vaginal cancer	0.000715	0.00101	CbGeAlD
Bosutinib—ABL1—mammalian vulva—vaginal cancer	0.000713	0.001	CbGeAlD
Bosutinib—TXK—Immune System—IFNA1—vaginal cancer	0.000706	0.00245	CbGpPWpGaD
Bosutinib—PRKCQ—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000703	0.00243	CbGpPWpGaD
Bosutinib—CSF1R—female gonad—vaginal cancer	0.000702	0.000988	CbGeAlD
Bosutinib—EGFR—SHP2 signaling—IL2—vaginal cancer	0.000702	0.00243	CbGpPWpGaD
Bosutinib—CSF1R—vagina—vaginal cancer	0.000698	0.000982	CbGeAlD
Bosutinib—PDGFRB—female reproductive system—vaginal cancer	0.000685	0.000963	CbGeAlD
Bosutinib—TBK1—Innate Immune System—IFNA1—vaginal cancer	0.000683	0.00237	CbGpPWpGaD
Bosutinib—ABL1—uterus—vaginal cancer	0.000679	0.000954	CbGeAlD
Bosutinib—CSK—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000679	0.00235	CbGpPWpGaD
Bosutinib—MAP3K7—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000679	0.00235	CbGpPWpGaD
Bosutinib—LCK—SHP2 signaling—IL2—vaginal cancer	0.000677	0.00234	CbGpPWpGaD
Bosutinib—YES1—Signaling by Interleukins—IL2—vaginal cancer	0.000673	0.00233	CbGpPWpGaD
Bosutinib—PTK2—Immune System—EIF4A3—vaginal cancer	0.000673	0.00233	CbGpPWpGaD
Bosutinib—YES1—Immune System—EIF4A3—vaginal cancer	0.000664	0.0023	CbGpPWpGaD
Bosutinib—LCK—IL12-mediated signaling events—IL2—vaginal cancer	0.000659	0.00228	CbGpPWpGaD
Bosutinib—IRAK1—Signaling by Interleukins—IL2—vaginal cancer	0.000639	0.00221	CbGpPWpGaD
Bosutinib—BTK—Innate Immune System—IFNA1—vaginal cancer	0.000637	0.00221	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—EIF4A3—vaginal cancer	0.00063	0.00218	CbGpPWpGaD
Bosutinib—PDGFRB—female gonad—vaginal cancer	0.000623	0.000876	CbGeAlD
Bosutinib—PDGFRB—vagina—vaginal cancer	0.000619	0.000871	CbGeAlD
Bosutinib—EGFR—Regulation of Telomerase—IL2—vaginal cancer	0.000618	0.00214	CbGpPWpGaD
Bosutinib—ABL1—female reproductive system—vaginal cancer	0.00061	0.000858	CbGeAlD
Bosutinib—IRAK4—Innate Immune System—IFNA1—vaginal cancer	0.000609	0.00211	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling by Interleukins—IL2—vaginal cancer	0.000601	0.00208	CbGpPWpGaD
Bosutinib—MAP2K2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000593	0.00205	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—EIF4A3—vaginal cancer	0.000593	0.00205	CbGpPWpGaD
Bosutinib—SYK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000592	0.00205	CbGpPWpGaD
Bosutinib—FGR—Hemostasis—IFNA1—vaginal cancer	0.000586	0.00203	CbGpPWpGaD
Bosutinib—HCK—Innate Immune System—IFNA1—vaginal cancer	0.000585	0.00202	CbGpPWpGaD
Bosutinib—LYN—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000567	0.00196	CbGpPWpGaD
Bosutinib—MAP2K1—Corticotropin-releasing hormone—IL2—vaginal cancer	0.000559	0.00194	CbGpPWpGaD
Bosutinib—FYN—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000558	0.00193	CbGpPWpGaD
Bosutinib—ABL1—female gonad—vaginal cancer	0.000555	0.000781	CbGeAlD
Bosutinib—MAP2K1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000555	0.00192	CbGpPWpGaD
Bosutinib—ABL1—vagina—vaginal cancer	0.000552	0.000776	CbGeAlD
Bosutinib—ERBB4—Innate Immune System—IFNA1—vaginal cancer	0.000551	0.00191	CbGpPWpGaD
Bosutinib—IKBKE—Immune System—IFNA1—vaginal cancer	0.000535	0.00185	CbGpPWpGaD
Bosutinib—FGR—Innate Immune System—IFNA1—vaginal cancer	0.000528	0.00183	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by Interleukins—IL2—vaginal cancer	0.000525	0.00182	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EIF4A3—vaginal cancer	0.000518	0.00179	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EIF4A3—vaginal cancer	0.000506	0.00175	CbGpPWpGaD
Bosutinib—LYN—Signaling by Interleukins—IL2—vaginal cancer	0.000502	0.00174	CbGpPWpGaD
Bosutinib—LYN—Immune System—EIF4A3—vaginal cancer	0.000495	0.00171	CbGpPWpGaD
Bosutinib—CAMK2G—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000494	0.00171	CbGpPWpGaD
Bosutinib—FYN—Signaling by Interleukins—IL2—vaginal cancer	0.000494	0.00171	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EIF4A3—vaginal cancer	0.000493	0.00171	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by Interleukins—IL2—vaginal cancer	0.000492	0.0017	CbGpPWpGaD
Bosutinib—FYN—Immune System—EIF4A3—vaginal cancer	0.000487	0.00169	CbGpPWpGaD
Bosutinib—ERBB3—Innate Immune System—IFNA1—vaginal cancer	0.000485	0.00168	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EIF4A3—vaginal cancer	0.000485	0.00168	CbGpPWpGaD
Bosutinib—MAP3K3—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000483	0.00167	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—IFNA1—vaginal cancer	0.00048	0.00166	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—IFNA1—vaginal cancer	0.000473	0.00164	CbGpPWpGaD
Bosutinib—WEE1—Hemostasis—IL2—vaginal cancer	0.000469	0.00163	CbGpPWpGaD
Bosutinib—SYK—Immune System—IFNA1—vaginal cancer	0.000468	0.00162	CbGpPWpGaD
Bosutinib—LCK—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000464	0.00161	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—IFNA1—vaginal cancer	0.000459	0.00159	CbGpPWpGaD
Bosutinib—IRAK4—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000449	0.00155	CbGpPWpGaD
Bosutinib—CSK—Immune System—IFNA1—vaginal cancer	0.000444	0.00154	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—IFNA1—vaginal cancer	0.000432	0.0015	CbGpPWpGaD
Bosutinib—HCK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000431	0.00149	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—IFNA1—vaginal cancer	0.000426	0.00148	CbGpPWpGaD
Bosutinib—EGFR—Immune System—EIF4A3—vaginal cancer	0.000421	0.00146	CbGpPWpGaD
Bosutinib—LCK—Signaling by Interleukins—IL2—vaginal cancer	0.000411	0.00142	CbGpPWpGaD
Bosutinib—LCK—Immune System—EIF4A3—vaginal cancer	0.000406	0.0014	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—IFNA1—vaginal cancer	0.000404	0.0014	CbGpPWpGaD
Bosutinib—PTK2B—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.0004	0.00139	CbGpPWpGaD
Bosutinib—TBK1—Immune System—IFNA1—vaginal cancer	0.000398	0.00138	CbGpPWpGaD
Bosutinib—EGFR—Spinal Cord Injury—IL2—vaginal cancer	0.000398	0.00138	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—IFNA1—vaginal cancer	0.00039	0.00135	CbGpPWpGaD
Bosutinib—PTK2—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000385	0.00133	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—IFNA1—vaginal cancer	0.000381	0.00132	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—IFNA1—vaginal cancer	0.00038	0.00132	CbGpPWpGaD
Bosutinib—BTK—Immune System—IFNA1—vaginal cancer	0.000371	0.00128	CbGpPWpGaD
Bosutinib—SYK—Hemostasis—IL2—vaginal cancer	0.000369	0.00128	CbGpPWpGaD
Bosutinib—PRKCQ—Hemostasis—IL2—vaginal cancer	0.000362	0.00125	CbGpPWpGaD
Bosutinib—SRC—Immune System—EIF4A3—vaginal cancer	0.000359	0.00124	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—IFNA1—vaginal cancer	0.000355	0.00123	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—IFNA1—vaginal cancer	0.000353	0.00122	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—IFNA1—vaginal cancer	0.000351	0.00122	CbGpPWpGaD
Bosutinib—CSK—Hemostasis—IL2—vaginal cancer	0.00035	0.00121	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—IFNA1—vaginal cancer	0.000347	0.0012	CbGpPWpGaD
Bosutinib—SRMS—Immune System—IL2—vaginal cancer	0.000344	0.00119	CbGpPWpGaD
Bosutinib—HCK—Immune System—IFNA1—vaginal cancer	0.00034	0.00118	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—IFNA1—vaginal cancer	0.000333	0.00115	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—IFNA1—vaginal cancer	0.000324	0.00112	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—IFNA1—vaginal cancer	0.000321	0.00111	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—IFNA1—vaginal cancer	0.000318	0.0011	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—IFNA1—vaginal cancer	0.000316	0.0011	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IFNA1—vaginal cancer	0.000316	0.00109	CbGpPWpGaD
Bosutinib—YES1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000314	0.00109	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IFNA1—vaginal cancer	0.000313	0.00108	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IFNA1—vaginal cancer	0.000311	0.00108	CbGpPWpGaD
Bosutinib—BLK—Immune System—IFNA1—vaginal cancer	0.000308	0.00107	CbGpPWpGaD
Bosutinib—CDK2—Hemostasis—IL2—vaginal cancer	0.000308	0.00107	CbGpPWpGaD
Bosutinib—FGR—Immune System—IFNA1—vaginal cancer	0.000307	0.00106	CbGpPWpGaD
Bosutinib—IRAK1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000298	0.00103	CbGpPWpGaD
Bosutinib—TXK—Immune System—IL2—vaginal cancer	0.000292	0.00101	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—IFNA1—vaginal cancer	0.000289	0.001	CbGpPWpGaD
Bosutinib—LYN—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000283	0.00098	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IFNA1—vaginal cancer	0.000283	0.000979	CbGpPWpGaD
Bosutinib—MAP3K7—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000281	0.000972	CbGpPWpGaD
Bosutinib—FYN—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000279	0.000965	CbGpPWpGaD
Bosutinib—ABCB1—Allograft Rejection—IL2—vaginal cancer	0.000277	0.000958	CbGpPWpGaD
Bosutinib—STK4—Signaling Pathways—IL2—vaginal cancer	0.000272	0.000943	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IFNA1—vaginal cancer	0.00027	0.000936	CbGpPWpGaD
Bosutinib—CYP3A4—female reproductive system—vaginal cancer	0.000268	0.000377	CbGeAlD
Bosutinib—LCK—Innate Immune System—IFNA1—vaginal cancer	0.00026	0.000902	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—IFNA1—vaginal cancer	0.000256	0.000887	CbGpPWpGaD
Bosutinib—ABCB1—epithelium—vaginal cancer	0.000255	0.000359	CbGeAlD
Bosutinib—ABCB1—uterine cervix—vaginal cancer	0.000253	0.000356	CbGeAlD
Bosutinib—PTK2—Immune System—IFNA1—vaginal cancer	0.000252	0.000871	CbGpPWpGaD
Bosutinib—YES1—Immune System—IFNA1—vaginal cancer	0.000248	0.000859	CbGpPWpGaD
Bosutinib—MAP2K2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000245	0.000849	CbGpPWpGaD
Bosutinib—FGR—Hemostasis—IL2—vaginal cancer	0.000242	0.00084	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IFNA1—vaginal cancer	0.000235	0.000815	CbGpPWpGaD
Bosutinib—LYN—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000234	0.000811	CbGpPWpGaD
Bosutinib—ABCB1—urethra—vaginal cancer	0.000233	0.000327	CbGeAlD
Bosutinib—LCK—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000232	0.000804	CbGpPWpGaD
Bosutinib—STK3—Signaling Pathways—IL2—vaginal cancer	0.000232	0.000802	CbGpPWpGaD
Bosutinib—FYN—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000231	0.000799	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IFNA1—vaginal cancer	0.000231	0.000798	CbGpPWpGaD
Bosutinib—MAP2K1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000229	0.000794	CbGpPWpGaD
Bosutinib—ABCB1—endometrium—vaginal cancer	0.000229	0.000322	CbGeAlD
Bosutinib—PRKCQ—GPCR downstream signaling—IL2—vaginal cancer	0.000229	0.000793	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IFNA1—vaginal cancer	0.000222	0.000767	CbGpPWpGaD
Bosutinib—ABCB1—mammalian vulva—vaginal cancer	0.000222	0.000312	CbGeAlD
Bosutinib—IKBKE—Immune System—IL2—vaginal cancer	0.000221	0.000767	CbGpPWpGaD
Bosutinib—ABCB1—uterus—vaginal cancer	0.000211	0.000297	CbGeAlD
Bosutinib—PRKCQ—Signaling by GPCR—IL2—vaginal cancer	0.000208	0.00072	CbGpPWpGaD
Bosutinib—SRC—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000205	0.000711	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—IL2—vaginal cancer	0.000198	0.000687	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—IL2—vaginal cancer	0.000196	0.000678	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—IL2—vaginal cancer	0.000194	0.000672	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IFNA1—vaginal cancer	0.000194	0.000671	CbGpPWpGaD
Bosutinib—SYK—Immune System—IL2—vaginal cancer	0.000193	0.00067	CbGpPWpGaD
Bosutinib—LCK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000192	0.000665	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—IL2—vaginal cancer	0.00019	0.000658	CbGpPWpGaD
Bosutinib—ABCB1—female reproductive system—vaginal cancer	0.00019	0.000267	CbGeAlD
Bosutinib—PDGFRB—Immune System—IFNA1—vaginal cancer	0.000189	0.000654	CbGpPWpGaD
Bosutinib—LYN—Immune System—IFNA1—vaginal cancer	0.000185	0.000641	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IFNA1—vaginal cancer	0.000184	0.000638	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—IL2—vaginal cancer	0.000184	0.000637	CbGpPWpGaD
Bosutinib—CSK—Immune System—IL2—vaginal cancer	0.000183	0.000635	CbGpPWpGaD
Bosutinib—FYN—Immune System—IFNA1—vaginal cancer	0.000182	0.000631	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IFNA1—vaginal cancer	0.000181	0.000627	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—IL2—vaginal cancer	0.000176	0.000608	CbGpPWpGaD
Bosutinib—ABCB1—female gonad—vaginal cancer	0.000173	0.000243	CbGeAlD
Bosutinib—ABCB1—vagina—vaginal cancer	0.000172	0.000241	CbGeAlD
Bosutinib—BCR—Signaling Pathways—IL2—vaginal cancer	0.000168	0.000583	CbGpPWpGaD
Bosutinib—TBK1—Immune System—IL2—vaginal cancer	0.000165	0.00057	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—IL2—vaginal cancer	0.000161	0.000559	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—IL2—vaginal cancer	0.000158	0.000546	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IFNA1—vaginal cancer	0.000157	0.000545	CbGpPWpGaD
Bosutinib—BTK—Immune System—IL2—vaginal cancer	0.000153	0.000531	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—IL2—vaginal cancer	0.000152	0.000525	CbGpPWpGaD
Bosutinib—LCK—Immune System—IFNA1—vaginal cancer	0.000152	0.000525	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—IL2—vaginal cancer	0.000147	0.000509	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—IL2—vaginal cancer	0.000147	0.000508	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—IL2—vaginal cancer	0.000146	0.000505	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—IL2—vaginal cancer	0.000145	0.000503	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—IL2—vaginal cancer	0.000144	0.000497	CbGpPWpGaD
Bosutinib—HCK—Immune System—IL2—vaginal cancer	0.000141	0.000487	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—IL2—vaginal cancer	0.000138	0.000477	CbGpPWpGaD
Bosutinib—SRC—Immune System—IFNA1—vaginal cancer	0.000134	0.000465	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—IL2—vaginal cancer	0.000133	0.000459	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL2—vaginal cancer	0.000131	0.000453	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL2—vaginal cancer	0.000128	0.000442	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL2—vaginal cancer	0.000127	0.00044	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL2—vaginal cancer	0.000125	0.000433	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL2—vaginal cancer	0.000123	0.000425	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL2—vaginal cancer	0.000123	0.000425	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—IL2—vaginal cancer	0.00012	0.000414	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL2—vaginal cancer	0.000119	0.000411	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL2—vaginal cancer	0.000117	0.000405	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—IL2—vaginal cancer	0.000106	0.000367	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL2—vaginal cancer	0.000104	0.00036	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL2—vaginal cancer	0.000103	0.000355	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL2—vaginal cancer	9.92e-05	0.000344	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL2—vaginal cancer	9.73e-05	0.000337	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL2—vaginal cancer	9.16e-05	0.000317	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL2—vaginal cancer	8.77e-05	0.000304	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL2—vaginal cancer	8.57e-05	0.000297	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL2—vaginal cancer	8.45e-05	0.000293	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL2—vaginal cancer	8.2e-05	0.000284	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL2—vaginal cancer	8.14e-05	0.000282	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL2—vaginal cancer	8.01e-05	0.000277	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL2—vaginal cancer	7.84e-05	0.000272	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL2—vaginal cancer	7.84e-05	0.000272	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL2—vaginal cancer	7.82e-05	0.000271	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL2—vaginal cancer	7.65e-05	0.000265	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL2—vaginal cancer	7.62e-05	0.000264	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL2—vaginal cancer	7.56e-05	0.000262	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL2—vaginal cancer	7.53e-05	0.000261	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL2—vaginal cancer	7.49e-05	0.000259	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL2—vaginal cancer	7.12e-05	0.000247	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL2—vaginal cancer	6.73e-05	0.000233	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL2—vaginal cancer	6.63e-05	0.00023	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL2—vaginal cancer	6.51e-05	0.000225	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL2—vaginal cancer	6.29e-05	0.000218	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL2—vaginal cancer	6.27e-05	0.000217	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL2—vaginal cancer	5.93e-05	0.000205	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL2—vaginal cancer	5.55e-05	0.000192	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—vaginal cancer	5.18e-05	0.000179	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—vaginal cancer	5.05e-05	0.000175	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—vaginal cancer	4.95e-05	0.000171	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—vaginal cancer	4.87e-05	0.000169	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—vaginal cancer	4.84e-05	0.000168	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—vaginal cancer	4.21e-05	0.000146	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—vaginal cancer	4.05e-05	0.00014	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—vaginal cancer	3.59e-05	0.000124	CbGpPWpGaD
